Humoral immune responses of dengue fever patients using epitope-specific serotype-2 virus-like particle antigens

PLoS ONE

Volumn 4, Issue 4, 2009, Pages

  Crill, Wayne D ^a   Hughes, Holly R ^a   Delorey, Mark J ^a   Chang, Gwong Jen J ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; VIRUS ENVELOPE PROTEIN; EPITOPE; MONOCLONAL ANTIBODY; PRIMER DNA; VIRUS ANTIBODY; VIRUS ANTIGEN;

ANIMAL CELL; ANTIBODY RESPONSE; ANTIGEN DETECTION; ANTIGEN SPECIFICITY; ARTICLE; CONTROLLED STUDY; CROSS REACTION; DENGUE; EPITOPE MAPPING; GENE TARGETING; GENETIC VARIABILITY; HUMAN; HUMORAL IMMUNITY; IMMUNOGLOBULIN PRODUCTION; IMMUNOLOCALIZATION; NONHUMAN; PROTEIN STRUCTURE; VIRUS NEUTRALIZATION; AMINO ACID SEQUENCE; BIOSYNTHESIS; CHEMICAL STRUCTURE; CHEMISTRY; IMMUNOLOGY; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PROTEIN CONFORMATION; SEQUENCE HOMOLOGY;

DENGUE VIRUS; MURINAE;

AMINO ACID SEQUENCE; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; BASE SEQUENCE; DENGUE; DNA PRIMERS; EPITOPE MAPPING; EPITOPES; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PROTEIN CONFORMATION; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 64249106079     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0004991     Document Type: Article

References (69)

1. Solomon T, Mallewa M (2001) Dengue and other emerging flaviviruses. J Infect 42: 104-115.
2. Gubler DJ (2006) Dengue/dengue haemorrhagic fever: history and current status. Novartis Found Symp 277: 3-16; discussion 16-22, 71-13, 251-253.
3. Mackenzie JS, Gubler DJ, Petersen LR (2004) Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses. Nat Med 10: S98-109.
4. Farrar J, Focks D, Gubler D, Barrera R, Guzman MG, et al. (2007) Towards a global dengue research agenda. Trop Med Int Health 12: 695-699.
5. Normile D (2007) Tropical diseases. Hunt for dengue vaccine heats up as the disease burden grows. Science 317: 1494-1495.
6. Whitehead SS, Blaney JE, Durbin AP, Murphy BR (2007) Prospects for a dengue virus vaccine. Nat Rev Microbiol 5: 518-528.
7. Tesh RB, Travassos da Rosa AP, Guzman H, Araujo TP, Xiao SY (2002) Immunization with heterologous flaviviruses protective against fatal West Nile encephalitis. Emerg Infect Dis 8: 245-251.
8. Calisher CH, Karabatsos N, Dalrymple JM, Shope RE, Porterfield JS, et al. (1989) Antigenic relationships between flaviviruses as determined by cross-neutralization tests with polyclonal antisera. J Gen Virol 70(Pt 1): 37-43.
9. Sabin AB (1952) Research on dengue during WWII. American Journal of Tropical Medicine and Hygiene 1: 30-50.
10. Kuno G, Chang GJ, Tsuchiya KR, Karabatsos N, Cropp CB (1998) Phylogeny of the genus Flavivirus. J Virol 72: 73-83.
11. Lindenbach BD, Rice CM (2003) Molecular biology of flaviviruses. Adv Virus Res 59: 23-61.
12. Kuhn RJ, Zhang W, Rossmann MG, Pletnev SV, Corver J, et al. (2002) Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell 108: 717-725.
13. Pokidysheva E, Zhang Y, Battisti AJ, Bator-Kelly CM, Chipman PR, et al. (2006) Cryo-EM reconstruction of dengue virus in complex with the carbohydrate recognition domain of DC-SIGN. Cell 124: 485-493.
14. Allison SL, Schalich J, Stiasny K, Mandl CW, Heinz FX (2001) Mutational evidence for an internal fusion peptide in flavivirus envelope protein E. J Virol 75: 4268-4275.
15. Modis Y, Ogata S, Clements D, Harrison SC (2003) A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc Natl Acad Sci U S A 100: 6986-6991.
16. Modis Y, Ogata S, Clements D, Harrison SC (2005) Variable surface epitopes in the crystal structure of dengue virus type 3 envelope glycoprotein. J Virol 79: 1223-1231.
17. Rey FA, Heinz FX, Mandl C, Kunz C, Harrison SC (1995) The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution. Nature 375: 291-298.
18. Roehrig JT, Bolin RA, Kelly RG (1998) Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica. Virology 246: 317-328.
19. Stiasny K, Kiermayr S, Holzmann H, Heinz FX (2006) Cryptic properties of a cluster of dominant flavivirus cross-reactive antigenic sites. J Virol 80: 9557-9568.
20. Crill WD, Chang GJ (2004) Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes. J Virol 78: 13975-13986.
21. Crill WD, Roehrig JT (2001) Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells. J Virol 75: 7769-7773.
22. Sukupolvi-Petty S, Austin SK, Purtha WE, Oliphant T, Nybakken GE, et al. (2007) Type- and Subcomplex-Specific Neutralizing Antibodies against Domain III of Dengue Virus Type 2 Envelope Protein Recognize Adjacent Epitopes. J Virol 81: 12816-12826.
23. Gromowski GD, Barrett AD (2007) Characterization of an antigenic site that contains a dominant, type-specific neutralization determinant on the envelope protein domain III (ED3) of dengue 2 virus. Virology 366: 349-360.
24. Gromowski GD, Barrett ND, Barrett AD (2008) Characterization of dengue virus complex-specific neutralizing epitopes on envelope protein domain III of dengue 2 virus. J Virol 82: 8828-8837.
25. Chiou SS, Crill WD, Chen LK, Chang GJ (2008) Enzyme-linked immunosorbent assays using novel Japanese encephalitis virus antigen improve the accuracy of clinical diagnosis of flavivirus infections. Clin Vaccine Immunol 15: 825-835.
26. Oliphant T, Nybakken GE, Austin SK, Xu Q, Bramson J, et al. (2007) Induction of epitope-specific neutralizing antibodies against West Nile virus. J Virol 81: 11828-11839.
27. Martin DA, Noga A, Kosoy O, Johnson AJ, Petersen LR, et al. (2004) Evaluation of a diagnostic algorithm using immunoglobulin M enzyme-linked immunosorbent assay to differentiate human West Nile Virus and St. Louis Encephalitis virus infections during the 2002 West Nile Virus epidemic in the United States. Clin Diagn Lab Immunol 11: 1130-1133.
28. Kuno G (2003) Serodiagnosis of flaviviral infections and vaccinations in humans. Adv Virus Res 61: 3-65.
29. Roberson JA, Crill WD, Chang GJ (2007) Differentiation of West Nile and St. Louis encephalitis virus infections by use of noninfectious virus-like particles with reduced cross-reactivity. J Clin Microbiol 45: 3167-3174.
30. Barrera R, Hunsperger E, Munoz-Jordan JL, Amador M, Diaz A, et al. (2008) First isolation of west nile virus in the Caribbean. Am J Trop Med Hyg 78: 666-668.
31. Detection of West Nile virus in blood donations-Puerto Rico, 2007. MMWR Morb Mortal Wkly Rep 57: 577-580.
32. Takada A, Kawaoka Y (2003) Antibody-dependent enhancement of viral infection: molecular mechanisms and in vivo implications. Rev Med Virol 13: 387-398.
33. Wallace MJ, Smith DW, Broom AK, Mackenzie JS, Hall RA, et al. (2003) Antibody-dependent enhancement of Murray Valley encephalitis virus virulence in mice. J Gen Virol 84: 1723-1728.
34. Halstead SB (1989) Antibody, macrophages, dengue virus infection, shock, and hemorrhage: a pathogenetic cascade. Rev Infect Dis 11 Suppl 4: S830-839.
35. Gubler DJ (2002) Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic problem in the 21st century. Trends Microbiol 10: 100-103.
36. Guzman MG, Alvarez M, Rodriguez-Roche R, Bernardo L, Montes T, et al. (2007) Neutralizing antibodies after infection with dengue 1 virus. Emerg Infect Dis 13: 282-286.
37. Chang GJ, Kuno G, Purdy DE, Davis BS (2004) Recent advancement in flavivirus vaccine development. Expert Rev Vaccines 3: 199-220.
38. Monath TP (2007) Dengue and yellow fever-challenges for the development and use of vaccines. N Engl J Med 357: 2222-2225.
39. Hombach J, Jane Cardosa M, Sabchareon A, Vaughn DW, Barrett AD (2007) Scientific consultation on immunological correlates of protection induced by dengue vaccines Report from a meeting held at the World Health Organization 17-18 November 2005. Vaccine.
40. Goncalvez AP, Engle RE, St Claire M, Purcell RH, Lai CJ (2007) Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention. Proc Natl Acad Sci U S A 104: 9422-9427.
41. Rigau-Perez JG (2006) Severe dengue: the need for new case definitions. Lancet Infect Dis 6: 297-302.
42. Senior K (2007) Dengue fever:what hope for control. The Lancet Infectious Diseases 7: 636.
43. Crill WD, Trainor NB, Chang GJ (2007) A detailed mutagenesis study of flavivirus cross-reactive epitopes using West Nile virus-like particles. J Gen Virol 88: 1169-1174.
44. Trainor NB, Crill WD, Roberson JA, Chang GJ (2007) Mutation analysis of the fusion domain region of St. Louis encephalitis virus envelope protein. Virology 360: 398-406.
45. Goncalvez AP, Purcell RH, Lai CJ (2004) Epitope determinants of a chimpanzee Fab antibody that efficiently cross-neutralizes dengue type 1 and type 2 viruses map to inside and in close proximity to fusion loop of the dengue type 2 virus envelope glycoprotein. J Virol 78: 12919-12928.
46. Oliphant T, Nybakken GE, Engle M, Xu Q, Nelson CA, et al. (2006) Antibody recognition and neutralization determinants on domains I and II of West Nile Virus envelope protein. J Virol 80: 12149-12159.
47. Lok SM, Kostyuchenko V, Nybakken GE, Holdaway HA, Battisti AJ, et al. (2008) Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins. Nat Struct Mol Biol 15: 312-317.
48. Lisova O, Hardy F, Petit V, Bedouelle H (2007) Mapping to completeness and transplantation of a group-specific, discontinuous, neutralizing epitope in the envelope protein of dengue virus. J Gen Virol 88: 2387-2397.
49. Blok J, Samuel S, Gibbs AJ, Vitarana UT (1989) Variation of the nucleotide and encoded amino acid sequences of the envelope gene from eight dengue-2 viruses. Arch Virol 105: 39-53.
50. Kuno G, Artsob H, Karabatsos N, Tsuchiya KR, Chang GJ (2001) Genomic sequencing of deer tick virus and phylogeny of powassan-related viruses of North America. Am J Trop Med Hyg 65: 671-676.
51. Nitayaphan S, Grant JA, Chang GJ, Trent DW (1990) Nucleotide sequence of the virulent SA-14 strain of Japanese encephalitis virus and its attenuated vaccine derivative, SA-14-14-2. Virology 177: 541-552.
52. Maillard RA, Jordan M, Beasley DW, Barrett AD, Lee JC (2008) Long range communication in the envelope protein domain III and its effect on the resistance of West Nile virus to antibody-mediated neutralization. J Biol Chem 283: 613-622.
53. Trirawatanapong T, Chandran B, Putnak R, Padmanabhan R (1992) Mapping of a region of dengue virus type-2 glycoprotein required for binding by a neutralizing monoclonal antibody. Gene 116: 139-150.
54. Lin B, Parrish CR, Murray JM, Wright PJ (1994) Localization of a neutralizing epitope on the envelope protein of dengue virus type 2. Virology 202: 885-890.
55. Lok SM, Ng ML, Aaskov J (2001) Amino acid and phenotypic changes in dengue 2 virus associated with escape from neutralisation by IgM antibody. J Med Virol 65: 315-323.
56. Hiramatsu K, Tadano M, Men R, Lai CJ (1996) Mutational analysis of a neutralization epitope on the dengue type 2 virus (DEN2) envelope protein: monoclonal antibody resistant DEN2/DEN4 chimeras exhibit reduced mouse neurovirulence. Virology 224: 437-445.
57. Lai CJ, Goncalvez AP, Men R, Wernly C, Donau O, et al. (2007) Epitope determinants of a chimpanzee dengue virus type 4 (DENV-4)-neutralizing antibody and protection against DEN-4 challenge in mice and rhesus monkeys by passively transferred humanized antibody. Journal of Virology 81: 12766-12774.
58. Lai CY, Tsai WY, Lin SR, Kao CL, Hu HP, et al. (2008) Antibodies to envelope glycoprotein of dengue virus during the natural course of infection are predominantly cross-reactive and recognize epitopes containing highly conserved residues at the fusion loop of domain II. J Virol 82: 6631-6643.
59. Johnson AJ, Martin DA, Karabatsos N, Roehrig JT (2000) Detection of anti-arboviral immunoglobulin G by using a monoclonal antibody-based capture enzyme-linked immunosorbent assay. J Clin Microbiol 38: 1827-1831.
60. Halstead SB (2003) Neutralization and antibody-dependent enhancement of dengue viruses. Adv Virus Res 60: 421-467.
61. Gonzalez D, Castro OE, Kouri G, Perez J, Martinez E, et al. (2005) Classical dengue hemorrhagic fever resulting from two dengue infections spaced 20 years or more apart: Havana, Dengue 3 epidemic, 2001-2002. Int J Infect Dis 9: 280-285.
62. Throsby M, Geuijen C, Goudsmit J, Bakker AQ, Korimbocus J, et al. (2006) Isolation and characterization of human monoclonal antibodies from individuals infected with West Nile Virus. J Virol 80: 6982-6992.
63. Chang GJ, Hunt AR, Holmes DA, Springfield T, Chiueh TS, et al. (2003) Enhancing biosynthesis and secretion of premembrane and envelope proteins by the chimeric plasmid of dengue virus type 2 and Japanese encephalitis virus. Virology 306: 170-180.
64. Chang GJ, Hunt AR, Davis B (2000) A single intramuscular injection of recombinant plasmid DNA induces protective immunity and prevents Japanese encephalitis in mice. J Virol 74: 4244-4252.
65. Henchal EA, McCown JM, Burke DS, Seguin MC, Brandt WE (1985) Epitopic analysis of antigenic determinants on the surface of dengue-2 virions using monoclonal antibodies. Am J Trop Med Hyg 34: 162-169.
66. Martin DA, Biggerstaff BJ, Allen B, Johnson AJ, Lanciotti RS, et al. (2002) Use of immunoglobulin m cross-reactions in differential diagnosis of human flaviviral encephalitis infections in the United States. Clin Diagn Lab Immunol 9: 544-549.
67. Shu PY, Chen LK, Chang SF, Yueh YY, Chow L, et al. (2003) Comparison of capture immunoglobulin M (IgM) and IgG enzyme-linked immunosorbent assay (ELISA) and nonstructural protein NS1 serotype-specific IgG ELISA for differentiation of primary and secondary dengue virus infections. Clin Diagn Lab Immunol 10: 622-630.
68. Lehmann EL, Casella G (1998) Theory of Point Estimation. Springer Verlag.
69. Casella G, Berger RL (1990) Statistical Inference. Belmont: Wadsworth, Inc.